Skip to search formSkip to main contentSkip to account menu

PNU 159682

Known as: 3'-deamino-3'',4'-anhydro-(2''(S)-methoxy-3''(R)-oxy-4''-morpholinyl)doxorubicin, PNU-159682 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 1541: Evaluation of ROR1 targeted antibody drug conjugate in ROR1 positive leukemia
Introduction: Receptor tyrosine kinase like orphan receptor 1 (ROR1) is expressed on the surface of multiple blood and solid… 
2019
2019
Abstract LB-197: NBE-002, an anthracycline-based immune-stimulatory antibody drug conjugate (iADC) targeting ROR1 for the treatment of triple-negative breast cancer
Introduction: We report on the development and preclinical validation of NBE-002, a next-generation antibody drug conjugate (ADC… 
2018
2018
Abstract 737: Antibody drug conjugates with anthracycline payload induce tumor-selective antitumor immunity and exhibit a favorable safety profile in cynomolgus monkey toxicology studies
  • U. Grawunder
  • Experimental and Molecular Therapeutics
  • 2018
  • Corpus ID: 81241385
Background: Antibody Drug Conjugates (ADCs) target highly potent small molecule cytotoxic agents to tumors via tumor-specific… 
2018
2018
PROTOCOL Product Data Sheet Inhibitors
  • 2018
  • Corpus ID: 53941442
In Vitro PNU-159682 inhibits a panel of human tumor cell lines with IC70 values in the range of 0.07-0.58 nM, and is 2,360to 790… 
2013
2013
Abstract 4634: Anthracycline based antibody-drug conjugates (ADCs) for the treatment of non-Hodgkin's lymphoma are effective in cell lines resistant to auristatin based ADCs.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Anthracyclines are one of the most widely used… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)